{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T23:46:48Z","timestamp":1770767208615,"version":"3.50.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,6,7]],"date-time":"2022-06-07T00:00:00Z","timestamp":1654560000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,6,7]],"date-time":"2022-06-07T00:00:00Z","timestamp":1654560000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Harm Reduct J"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Traditional heroin-assisted treatment in Switzerland consists of oral and injectable diacetylmorphine (pharmaceutical heroin) administration. To date, no suitable treatment option is available for patients who crave rapid onset (\u201crush\u201d) but are either unable to inject or primarily sniff or inhale illicit heroin. We present a patient who successfully switched to intranasal heroin-assisted treatment following several unsuccessful treatment attempts.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Case presentation<\/jats:title>\n                <jats:p>A 29-year-old male with severe opioid use disorder, injection substance use, and concomitant cocaine use, previously prescribed slow-release oral morphine, was started on intravenous diacetylmorphine. Due to complications and harms associated with intravenous injections, nasal diacetylmorphine was prescribed. With this novel route of administration, the patient who had previously been unable to adhere to other OAT options remained in treatment. Health outcomes improved by reduction of injection-related harms, increased adherence to the heroin-assisted treatment regimen, and increased collaboration with the therapeutic staff.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Nasal heroin-assisted treatment can be a feasible therapeutic option for individuals with severe opioid use disorder who crave the fast onset of effect of diacetylmorphine but are unable to inject intravenously.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12954-022-00644-2","type":"journal-article","created":{"date-parts":[[2022,6,7]],"date-time":"2022-06-07T10:03:25Z","timestamp":1654596205000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Nasal administration of diacetylmorphine improved the adherence in a patient receiving heroin-assisted treatment"],"prefix":"10.1186","volume":"19","author":[{"given":"Maximilian","family":"Meyer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean N.","family":"Westenberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johannes","family":"Strasser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenneth M.","family":"D\u00fcrsteler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Undine E.","family":"Lang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Krausz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc","family":"Vogel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,6,7]]},"reference":[{"key":"644_CR1","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1111\/j.1360-0443.2009.02741.x","volume":"105","author":"A Uchtenhagen","year":"2010","unstructured":"Uchtenhagen A. Heroin-assisted treatment in Switzerland: a case study in policy change. Addiction. 2010;105:29\u201337. https:\/\/doi.org\/10.1111\/j.1360-0443.2009.02741.x.","journal-title":"Addiction"},{"key":"644_CR2","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1192\/bjp.bp.114.149195","volume":"207","author":"J Strang","year":"2015","unstructured":"Strang J, Groshkova T, Uchtenhagen A, Van Den Brink W, Haasen C, Schechter MT, et al. Heroin on trial: systematic review and meta-analysis of randomised trials of diamorphine-prescribing as treatment for refractory heroin addiction. Br J Psychiatry. 2015;207:5\u201314. https:\/\/doi.org\/10.1192\/bjp.bp.114.149195.","journal-title":"Br J Psychiatry"},{"key":"644_CR3","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1056\/nejmoa0810635","volume":"361","author":"E Oviedo-Joekes","year":"2009","unstructured":"Oviedo-Joekes E, Brissette S, Marsh DC, Lauzon P, Guh D, Anis A, et al. Diacetylmorphine versus methadone for the treatment of opioid addiction. N Engl J Med. 2009;361:777\u201386. https:\/\/doi.org\/10.1056\/nejmoa0810635.","journal-title":"N Engl J Med"},{"key":"644_CR4","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.cd003410.pub4","author":"M Ferri","year":"2011","unstructured":"Ferri M, Davoli M, Perucci CA. Heroin maintenance for chronic heroin-dependent individuals. Cochrane Database Syst Rev. 2011. https:\/\/doi.org\/10.1002\/14651858.cd003410.pub4.","journal-title":"Cochrane Database Syst Rev"},{"key":"644_CR5","unstructured":"Swiss Federal Council. Art. 13 - SR 812.121.6 - Verordnung vom 25. Mai 2011 \u00fcber Bet\u00e4ubungsmittelsucht und andere suchtbedingte St\u00f6rungen (Bet\u00e4ubungsmittelsuchtverordnung, BetmSV). 2011. https:\/\/www.fedlex.admin.ch\/eli\/cc\/2011\/364\/de#art_13. Accessed 17 April 2022."},{"key":"644_CR6","doi-asserted-by":"publisher","DOI":"10.1186\/s12954-020-00412-0","author":"M Liebrenz","year":"2020","unstructured":"Liebrenz M, Gamma A, Buadze A, Schleifer R, Baggio S, Schwartz B, et al. Fifteen years of heroin-assisted treatment in a Swiss prison: a retrospective cohort study. Harm Reduct J. 2020. https:\/\/doi.org\/10.1186\/s12954-020-00412-0.","journal-title":"Harm Reduct J"},{"key":"644_CR7","unstructured":"Swiss Federal Council. Art. 10 - SR 812.121.6 - Verordnung vom 25. Mai 2011 \u00fcber Bet\u00e4ubungsmittelsucht und andere suchtbedingte St\u00f6rungen (Bet\u00e4ubungsmittelsuchtverordnung, BetmSV). https:\/\/www.fedlex.admin.ch\/eli\/cc\/2011\/364\/de#art_10. Accessed 18 April 2022."},{"key":"644_CR8","doi-asserted-by":"publisher","first-page":"103548","DOI":"10.1016\/j.drugpo.2021.103548","volume":"101","author":"M Meyer","year":"2022","unstructured":"Meyer M, Strasser J, K\u00f6ck P, Walter M, Vogel M, D\u00fcrsteler KM. Experiences with take-home dosing in heroin-assisted treatment in Switzerland during the COVID-19 pandemic\u2013Is an update of legal restrictions warranted? Int J Drug Policy. 2022;101:103548. https:\/\/doi.org\/10.1016\/j.drugpo.2021.103548.","journal-title":"Int J Drug Policy"},{"key":"644_CR9","unstructured":"Bundesamt f\u00fcr Gesundheit. Handbuch Heroingest\u00fctzte Behandlung: Richtlinien, Empfehlungen, Information. 2000."},{"key":"644_CR10","doi-asserted-by":"publisher","unstructured":"EMCDDA. European Drug Report 2021 - Trends and Developments. 2021. https:\/\/doi.org\/10.2810\/725386.","DOI":"10.2810\/725386"},{"key":"644_CR11","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/S0009-9236(03)00199-1","volume":"74","author":"F Girardin","year":"2003","unstructured":"Girardin F, Rentsch KM, Schwab MA, Maggiorini M, Pauli-Magnus C, Kullak-Ublick GA, et al. Pharmacokinetics of high doses of intramuscular and oral heroin in narcotic addicts. Clin Pharmacol Ther. 2003;74:341\u201352. https:\/\/doi.org\/10.1016\/S0009-9236(03)00199-1.","journal-title":"Clin Pharmacol Ther"},{"key":"644_CR12","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1007\/s002130050956","volume":"143","author":"SD Comer","year":"1999","unstructured":"Comer SD, Collins ED, MacArthur RB, Fischman MW. Comparison of intravenous and intranasal heroin self-administration by morphine-maintained humans. Psychopharmacology. 1999;143:327\u201338. https:\/\/doi.org\/10.1007\/s002130050956.","journal-title":"Psychopharmacology"},{"key":"644_CR13","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1111\/j.1742-7843.2006.pto_233.x","volume":"98","author":"EJ Rook","year":"2006","unstructured":"Rook EJ, Van Ree JM, Van Den Brink W, Hillebrand MJX, Huitema ADR, Hendriks VM, et al. Pharmacokinetics and pharmacodynamics of high doses of pharmaceutically prepared heroin, by intravenous or by inhalation route in opioid-dependent patients. Basic Clin Pharmacol Toxicol. 2006;98:86\u201396. https:\/\/doi.org\/10.1111\/j.1742-7843.2006.pto_233.x.","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"644_CR14","first-page":"267","volume":"19","author":"M Vogel","year":"2017","unstructured":"Vogel M, Strasser J. Alternativen in der Behandlung mit im Zentralnervensystem rasch anflutenden Opioiden. Suchtmedizin. 2017;19:267\u201374.","journal-title":"Suchtmedizin"},{"key":"644_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1747-597X-6-9","volume":"6","author":"KM D\u00fcrsteler-MacFarland","year":"2011","unstructured":"D\u00fcrsteler-MacFarland KM, Vogel M, Wiesbeck GA, Petitjean SA. There is no age limit for methadone: a retrospective cohort study. Subst Abus Treat Prev Policy. 2011;6:1\u20138. https:\/\/doi.org\/10.1186\/1747-597X-6-9.","journal-title":"Subst Abus Treat Prev Policy"},{"key":"644_CR16","unstructured":"Pirona A, Guarita B, Montanari L, Noor A. Ageing and addiction: challenges for treatment systems. EMCDDA. 2015. https:\/\/www.emcdda.europa.eu\/publications\/posters\/2016\/ageing-and-addiction-challenges-treatment-systems_en. Accessed 20 April 2022."},{"key":"644_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2020.108267","author":"S Colledge","year":"2020","unstructured":"Colledge S, Larney S, Bruno R, Gibbs D, Degenhardt L, Yuen WS, et al. Profile and correlates of injecting-related injuries and diseases among people who inject drugs in Australia. Drug Alcohol Depend. 2020. https:\/\/doi.org\/10.1016\/j.drugalcdep.2020.108267.","journal-title":"Drug Alcohol Depend"},{"key":"644_CR18","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1159\/000516431","volume":"28","author":"M Vogel","year":"2022","unstructured":"Vogel M, K\u00f6ck P, Strasser J, Kalbermatten C, Binder H, D\u00fcrsteler KM, et al. Nasal opioid agonist treatment in patients with severe opioid dependence: a case series. Eur Addict Res. 2022;28:80\u20136. https:\/\/doi.org\/10.1159\/000516431.","journal-title":"Eur Addict Res"},{"key":"644_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13011-021-00358-x","volume":"16","author":"E Oviedo-Joekes","year":"2021","unstructured":"Oviedo-Joekes E, MacDonald S, Boissonneault C, Harper K. Take home injectable opioids for opioid use disorder during and after the COVID-19 Pandemic is in urgent need: a case study. Subst Abus Treat Prev Policy. 2021;16:1\u20137. https:\/\/doi.org\/10.1186\/s13011-021-00358-x.","journal-title":"Subst Abus Treat Prev Policy"},{"key":"644_CR20","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1111\/add.14442","volume":"114","author":"C Nordt","year":"2019","unstructured":"Nordt C, Vogel M, Dey M, Moldovanyi A, Beck T, Berthel T, et al. One size does not fit all\u2014evolution of opioid agonist treatments in a naturalistic setting over 23 years. Addiction. 2019;114:103\u201311. https:\/\/doi.org\/10.1111\/add.14442.","journal-title":"Addiction"},{"key":"644_CR21","first-page":"57","volume":"17","author":"M Vogel","year":"2015","unstructured":"Vogel M, D\u00fcrsteler K, Strasser J, Schmid O, M\u00fcller E, Himmelheber P, et al. Injektionen in die Leistenvene: Pr\u00e4valenz und Umgang in heroingest\u00fctzter Behandlung. Suchtmedizin. 2015;17:57\u201362.","journal-title":"Suchtmedizin"},{"key":"644_CR22","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1186\/s12954-021-00584-3","volume":"18","author":"M Meyer","year":"2021","unstructured":"Meyer M, Eichenberger R, Strasser J, D\u00fcrsteler KM, Vogel M. \u00abOne prick and then it\u00b4s done\u00bb: a mixed-methods exploratory study on intramuscular injection in heroin-assisted treatment. Harm Reduct J. 2021;18:134. https:\/\/doi.org\/10.1186\/s12954-021-00584-3.","journal-title":"Harm Reduct J"},{"key":"644_CR23","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.drugalcdep.2016.11.029","volume":"171","author":"S Larney","year":"2017","unstructured":"Larney S, Peacock A, Mathers BM, Hickman M, Degenhardt L. A systematic review of injecting-related injury and disease among people who inject drugs. Drug Alcohol Depend. 2017;171:39\u201349.","journal-title":"Drug Alcohol Depend"},{"key":"644_CR24","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.drugpo.2015.11.003","volume":"28","author":"VDD Hope","year":"2016","unstructured":"Hope VDD, Parry JVV, Ncube F, Hickman M. Not in the vein: \u2018missed hits\u2019, subcutaneous and intramuscular injections and associated harms among people who inject psychoactive drugs in Bristol, United Kingdom. Int J Drug Policy. 2016;28:83\u201390.","journal-title":"Int J Drug Policy"}],"container-title":["Harm Reduction Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-022-00644-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12954-022-00644-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-022-00644-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,7]],"date-time":"2022-06-07T22:07:10Z","timestamp":1654639630000},"score":1,"resource":{"primary":{"URL":"https:\/\/harmreductionjournal.biomedcentral.com\/articles\/10.1186\/s12954-022-00644-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,7]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["644"],"URL":"https:\/\/doi.org\/10.1186\/s12954-022-00644-2","relation":{},"ISSN":["1477-7517"],"issn-type":[{"value":"1477-7517","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,7]]},"assertion":[{"value":"29 April 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 May 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 June 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The case report was generated from existing data; consent to participate is not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Consent for publication was provided by the patient in writing.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All authors of the present manuscript declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"63"}}